Abstract
The seven-spanning transmembrane G-protein coupled receptor CXCR4, which specifically binds to the chemokine CXCL12, is expressed on many cell types, including various types of tumour cells. CXCR4 plays a crucial role in organ-specific metastasis, directing migration of malignant cells expressing this receptor toward microenvironments where the cognate ligand is secreted. CXCL12 has a direct growth and survival-promoting effect for various cancer cells and enhances moreover tumour angiogenesis by recruiting endothelial progenitor cells to tumours. Drugs which modulate the CXCL12/CXCR4 axis are therefore promising candidates in anti-cancer therapies. CXCR4 is also a coreceptor for human immunodeficiency virus type 1 (HIV-1) X4 virus and, as such, plays an important role in virus entry into target cells. Hence, antiviral agents that bind to CXCR4 are expected to inhibit HIV-1 entry. Here we review the structure, mechanism of action and biological activity of the main CXCR4 antagonists (peptide inhibitors, non-peptide antagonists, neutralizing antibodies, modified analogues of CXCL12) and agonists (CXCL12 peptide analogues) and discuss the CXCL12/CXCR4 axis as an important target in development of anti-tumoral and anti-HIV-1 therapies.
Keywords: CXCR4, CXCL12, antagonist, agonist, analogue, cancer, HIV-1, hematopoietic progenitor mobilization, cognate ligand, angiogenesis, human immunodeficiency virus type 1, peptide inhibitors,, chemokine receptors, G-protein coupled receptor (GPCR), bone marrow, lymph nodes, lung, brain, liver, peptide, Tachypleus tridentatus, Limulus polyphemus, TZ14004, TN14003, TC14012, 4F-benzoyl-TN14003, T-140-Based Cyclic Pentapeptides, Linear T140-Based Oligopeptides, tripeptide mimetics, p-fluorobenzoylated tripeptide mimetics, AMD3100, AMD3100-Based Non-Cyclam Compounds, Dipicolylamine zinc(II)-Based Compounds, HSEFFR-CPC-RFFESH, aberrant hematopoiesi, homodimerization, Epstein-Barr virus-encoded
Current Medicinal Chemistry
Title: The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection
Volume: 18 Issue: 4
Author(s): L. Patrussi and C. T. Baldari
Affiliation:
Keywords: CXCR4, CXCL12, antagonist, agonist, analogue, cancer, HIV-1, hematopoietic progenitor mobilization, cognate ligand, angiogenesis, human immunodeficiency virus type 1, peptide inhibitors,, chemokine receptors, G-protein coupled receptor (GPCR), bone marrow, lymph nodes, lung, brain, liver, peptide, Tachypleus tridentatus, Limulus polyphemus, TZ14004, TN14003, TC14012, 4F-benzoyl-TN14003, T-140-Based Cyclic Pentapeptides, Linear T140-Based Oligopeptides, tripeptide mimetics, p-fluorobenzoylated tripeptide mimetics, AMD3100, AMD3100-Based Non-Cyclam Compounds, Dipicolylamine zinc(II)-Based Compounds, HSEFFR-CPC-RFFESH, aberrant hematopoiesi, homodimerization, Epstein-Barr virus-encoded
Abstract: The seven-spanning transmembrane G-protein coupled receptor CXCR4, which specifically binds to the chemokine CXCL12, is expressed on many cell types, including various types of tumour cells. CXCR4 plays a crucial role in organ-specific metastasis, directing migration of malignant cells expressing this receptor toward microenvironments where the cognate ligand is secreted. CXCL12 has a direct growth and survival-promoting effect for various cancer cells and enhances moreover tumour angiogenesis by recruiting endothelial progenitor cells to tumours. Drugs which modulate the CXCL12/CXCR4 axis are therefore promising candidates in anti-cancer therapies. CXCR4 is also a coreceptor for human immunodeficiency virus type 1 (HIV-1) X4 virus and, as such, plays an important role in virus entry into target cells. Hence, antiviral agents that bind to CXCR4 are expected to inhibit HIV-1 entry. Here we review the structure, mechanism of action and biological activity of the main CXCR4 antagonists (peptide inhibitors, non-peptide antagonists, neutralizing antibodies, modified analogues of CXCL12) and agonists (CXCL12 peptide analogues) and discuss the CXCL12/CXCR4 axis as an important target in development of anti-tumoral and anti-HIV-1 therapies.
Export Options
About this article
Cite this article as:
Patrussi L. and T. Baldari C., The CXCL12/CXCR4 Axis as a Therapeutic Target in Cancer and HIV-1 Infection, Current Medicinal Chemistry 2011; 18 (4) . https://dx.doi.org/10.2174/092986711794480159
DOI https://dx.doi.org/10.2174/092986711794480159 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Exploring the Mechanism of Yi-Jing Decoction in Treating Polycystic Ovary Syndrome by Using Network Pharmacology
Current Medicinal Chemistry How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer
Current Pharmaceutical Biotechnology Reproductive and Endocrine Effects of p-Nonylphenol and Methoxychlor: A Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synthesis and Biological Evaluation of Aromatase Inhibitors
Letters in Drug Design & Discovery Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer
Current Pharmaceutical Biotechnology Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Hsa_circ_0000437 Inhibits the Development of Endometrial Carcinoma through miR-626/CDKN1B Axis
Protein & Peptide Letters Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Medicinal Attributes of Imidazo[1,2-a]pyridine Derivatives: An Update
Current Topics in Medicinal Chemistry Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design Editorial: Drug Targets and Biomarkers for Obstetric/Gynecologic/Reproductive Diseases
Current Drug Targets A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma
Combinatorial Chemistry & High Throughput Screening Lipoprotein(a): Current Perspectives
Current Vascular Pharmacology